TG Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.46 Insider Own8.00% Shs Outstand134.40M Perf Week6.83%
Market Cap818.74M Forward P/E- EPS next Y-1.50 Insider Trans-1.41% Shs Float132.75M Perf Month-15.98%
Income-326.50M PEG- EPS next Q-0.50 Inst Own70.80% Short Float14.71% Perf Quarter-45.68%
Sales7.90M P/S103.64 EPS this Y-8.70% Inst Trans-0.14% Short Ratio7.94 Perf Half Y-77.10%
Book/sh1.27 P/B4.80 EPS next Y2.00% ROA-83.00% Target Price19.57 Perf Year-81.25%
Cash/sh1.74 P/C3.51 EPS next 5Y- ROE-118.50% 52W Range5.51 - 41.00 Perf YTD-67.89%
Dividend- P/FCF- EPS past 5Y-10.50% ROI-113.00% 52W High-85.85% Beta2.25
Dividend %- Quick Ratio4.40 Sales past 5Y113.10% Gross Margin88.80% 52W Low5.26% ATR0.73
Employees219 Current Ratio4.40 Sales Q/Q150.00% Oper. Margin- RSI (14)36.96 Volatility8.61% 9.91%
OptionableYes Debt/Eq0.39 EPS Q/Q25.30% Profit Margin- Rel Volume1.31 Prev Close6.10
ShortableYes LT Debt/Eq0.39 EarningsMar 01 BMO Payout- Avg Volume2.46M Price5.80
Recom2.00 SMA20-15.30% SMA50-30.58% SMA200-69.25% Volume2,080,492 Change-4.92%
Feb-23-22Reiterated B. Riley Securities Buy $49 → $35
Nov-15-21Downgrade Goldman Neutral → Sell $33 → $26
Apr-20-21Initiated Goldman Neutral $50
Apr-19-21Reiterated H.C. Wainwright Buy $79 → $89
Sep-01-20Initiated JP Morgan Overweight $38
Aug-11-20Reiterated H.C. Wainwright Buy $32 → $38
Jun-05-20Initiated Evercore ISI Outperform $60
Jan-17-20Reiterated H.C. Wainwright Buy $20 → $24
Nov-27-19Resumed B. Riley FBR Buy $12
Feb-06-19Resumed Jefferies Buy $8
Sep-25-18Downgrade Raymond James Strong Buy → Outperform
Mar-09-18Reiterated B. Riley FBR, Inc. Buy $21.50 → $27
Dec-01-17Resumed B. Riley FBR, Inc. Buy $21.50
Nov-14-17Resumed H.C. Wainwright Buy $33
Apr-25-17Initiated Jefferies Buy
Mar-06-17Reiterated FBR & Co. Outperform $24 → $26
Oct-06-16Resumed Brean Capital Buy $28
May-27-16Initiated SunTrust Buy $18
Dec-01-15Initiated FBR Capital Outperform $29
Sep-09-15Initiated Raymond James Strong Buy
May-12-22 08:34AM  
May-05-22 08:15AM  
May-03-22 07:45AM  
May-02-22 03:00PM  
Apr-26-22 07:30AM  
Apr-19-22 11:02AM  
Apr-18-22 03:34PM  
Apr-15-22 08:30AM  
Apr-06-22 07:30AM  
Apr-04-22 07:44AM  
Mar-10-22 08:15AM  
Mar-04-22 08:56AM  
Mar-03-22 11:27AM  
Mar-01-22 08:45AM  
Feb-25-22 07:30AM  
Feb-24-22 08:05AM  
Feb-15-22 10:09AM  
Jan-31-22 02:04AM  
Jan-27-22 12:30PM  
Jan-24-22 07:30AM  
Jan-07-22 05:38PM  
Jan-05-22 07:30AM  
Jan-04-22 07:30AM  
Jan-03-22 01:59PM  
Dec-18-21 02:38AM  
Dec-16-21 04:00PM  
Dec-14-21 07:50PM  
Dec-13-21 10:40AM  
Dec-12-21 10:42PM  
Dec-10-21 07:30AM  
Dec-03-21 09:00PM  
Dec-02-21 10:02PM  
Dec-01-21 04:30PM  
Nov-30-21 05:34PM  
Nov-15-21 03:40PM  
Nov-09-21 07:30AM  
Nov-04-21 02:01PM  
Nov-03-21 03:17PM  
Nov-01-21 03:01PM  
Oct-18-21 04:04AM  
Oct-14-21 10:45AM  
Sep-30-21 07:30AM  
Sep-29-21 07:30AM  
Sep-23-21 08:00AM  
Sep-20-21 07:30AM  
Sep-13-21 09:21AM  
Sep-09-21 09:00AM  
Sep-03-21 01:11PM  
Aug-30-21 07:30AM  
Aug-16-21 10:15AM  
Aug-04-21 10:45AM  
Aug-02-21 02:47PM  
Jul-28-21 07:30AM  
Jul-22-21 08:06AM  
Jul-13-21 09:56AM  
Jul-09-21 07:30AM  
Jul-05-21 10:42AM  
Jun-30-21 07:24AM  
Jun-29-21 07:30AM  
Jun-18-21 02:00PM  
Jun-11-21 07:00AM  
Jun-09-21 07:00AM  
Jun-04-21 09:00AM  
May-27-21 07:30AM  
May-25-21 07:00AM  
May-13-21 07:30AM  
May-10-21 09:00PM  
May-07-21 09:20AM  
May-06-21 07:30AM  
May-04-21 08:57AM  
May-03-21 03:01PM  
Apr-26-21 08:24AM  
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. The company is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WEISS MICHAEL SCEO and PresidentJan 05Sale18.3130,671561,58610,988,021Jan 07 06:00 PM
Power Sean ACFO, Secretary and TreasurerJan 05Sale18.319,653176,746568,483Jan 07 06:11 PM
Power Sean ACFO, Secretary and TreasurerJan 04Sale19.2075,3121,445,990578,136Jan 07 06:11 PM
WEISS MICHAEL SCEO and PresidentJan 04Sale19.2037,549720,94113,455,697Jan 07 06:00 PM